Neeraj Agarwal, MD:So, what factors did I keep in mind when I was making a treatment decision for this patient? I think the first one was the IMDC risk factorhow many risk factors she had. She had 2 risk factors: presence of onset of metastatic disease within 1 year of surgery—within 1 year of diagnosis of localized kidney cancer—and high calcium. However, I also looked at her performance status. She was doing really well. She did not have really a lot of symptoms. She wanted to have an independent lifestyle. She did not want to visit me in the hospital multiple times. And, very importantly for me, the tumor did not express PD-L. So, upon PD-L1 testing, the tumor expression of PD-L1 was less than 1%, so those were the factors that I kept in mind while making a clinical decision for cabozantinib in this case.
For this patient with a newly diagnosed metastatic renal cell carcinoma, how do I pick which 1 to choose from? I have sunitinib, pazopanib, and cabozantinib. And very soon, nivolumab with ipilimumab will be approved.
Transcript edited for clarity.
Case Scenario: A 73-year old female with rapidly progressing mRCC
March 2017
December 2017
Comparing Choices for IO/TKI Combinations in Advanced RCC
May 2nd 2024During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on the combination of immunotherapy and tyrosine kinase inhibitors for patients with advanced renal cell carcinoma in the second article of a 2-part series.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Sustained Treatment-Free Survival in RCC Seen With Nivolumab and Ipilimumab
April 30th 2024Nivolumab monotherapy plus salvage nivolumab/ipilimumab demonstrated superior treatment-free survival rates among patients with advanced renal cell carcinoma, especially in patients with favorable risk profiles.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Advances in Subsequent Therapies Shake Up Sequencing of ccRCC Treatment
April 25th 2024With the approval of belzutifan and other newer data for treating patients with recurrent renal cell carcinoma, the state of subsequent therapies is advancing beyond the reuse of frontline options with impacts on duration of response and quality of life.
Read More
Ornstein Advises on Starting Dose and Management of Lenvatinib in RCC
April 21st 2024During a Case-Based Roundtable® event, Moshe Ornstein, MD, MA, provided guidance on dosing and toxicity concerns in a patient treated with lenvatinib plus pembrolizumab for advanced renal cell carcinoma.
Read More